BioSynchronicity Corporation is a USA based company founded and launched in June 2020 in the State of Washington. The global headquarters office was subsequently opened in Rochester, New York, in January, 2021. BioSynchronicity was tasked with designing and developing a reliable, simple, affordable, widely-available, and ultra-rapid SARS-CoV-2 antigen diagnostic test for hospital and point of care (POC) use, school and business screening programs, as well as self-administered testing at home through over-the-counter (OTC) sales where authorized by regulatory bodies. To meet this challenge, a global team of like-minded scientists, doctors, engineers, and other seasoned international business professionals was assembled, resulting in the creation of the innovative and accurate C-Sync™ COVID-19 Antigen Test, the C-SyncPlus™ COVID-19 Antigen Test, and the soon to be available C-Sync™ All-in-One COVID-19 Influenza A/B Combo Test.